Literature DB >> 26924880

Mixed-Effects Models with Skewed Distributions for Time-Varying Decay Rate in HIV Dynamics.

Ren Chen1, Yangxin Huang1.   

Abstract

After initiation of treatment, HIV viral load has multiphasic changes, which indicates that the viral decay rate is a time-varying process. Mixed-effects models with different time-varying decay rate functions have been proposed in literature. However, there are two unresolved critical issues: (i) it is not clear which model is more appropriate for practical use, and (ii) the model random errors are commonly assumed to follow a normal distribution, which may be unrealistic and can obscure important features of within- and among-subject variations. Because asymmetry of HIV viral load data is still noticeable even after transformation, it is important to use a more general distribution family that enables the unrealistic normal assumption to be relaxed. We developed skew-elliptical (SE) Bayesian mixed-effects models by considering the model random errors to have an SE distribution. We compared the performance among five SE models that have different time-varying decay rate functions. For each model, we also contrasted the performance under different model random error assumption such as normal, Student-t, skew-normal or skew-t distribution. Two AIDS clinical trial data sets were used to illustrate the proposed models and methods. The results indicate that the model with a time-varying viral decay rate that has two exponential components is preferred. Among the four distribution assumptions, the skew-t and skew-normal models provided better fitting to the data than normal or Student-t model, suggesting that it is important to assume a model with a skewed distribution in order to achieve reasonable results when the data exhibit skewness.

Entities:  

Keywords:  Bayesian analysis; HIV longitudinal dynamics; Mixed-effects models; Skew-elliptical distribution; Time-varying viral decay rate

Year:  2014        PMID: 26924880      PMCID: PMC4764139          DOI: 10.1080/03610918.2013.873129

Source DB:  PubMed          Journal:  Commun Stat Simul Comput        ISSN: 0361-0918            Impact factor:   1.118


  24 in total

1.  Ongoing HIV dissemination during HAART.

Authors:  Z Grossman; M Polis; M B Feinberg; Z Grossman; I Levi; S Jankelevich; R Yarchoan; J Boon; F de Wolf; J M Lange; J Goudsmit; D S Dimitrov; W E Paul
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

2.  A Bayesian approach to parameter estimation in HIV dynamical models.

Authors:  H Putter; S H Heisterkamp; J M A Lange; F de Wolf
Journal:  Stat Med       Date:  2002-08-15       Impact factor: 2.373

3.  Simultaneous inference for semiparametric nonlinear mixed-effects models with covariate measurement errors and missing responses.

Authors:  Wei Liu; Lang Wu
Journal:  Biometrics       Date:  2007-06       Impact factor: 2.571

4.  Joint inference for nonlinear mixed-effects models and time to event at the presence of missing data.

Authors:  Lang Wu; X Joan Hu; Hulin Wu
Journal:  Biostatistics       Date:  2007-08-29       Impact factor: 5.899

5.  Maximum likelihood estimation of long-term HIV dynamic models and antiviral response.

Authors:  Marc Lavielle; Adeline Samson; Ana Karina Fermin; France Mentré
Journal:  Biometrics       Date:  2011-03       Impact factor: 2.571

6.  Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics.

Authors:  A A Ding; H Wu
Journal:  Math Biosci       Date:  1999-08       Impact factor: 2.144

7.  Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.

Authors:  H Wu; D R Kuritzkes; D R McClernon; H Kessler; E Connick; A Landay; G Spear; M Heath-Chiozzi; F Rousseau; L Fox; J Spritzler; J M Leonard; M M Lederman
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

8.  Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

Authors:  Marc Pfister; Line Labbé; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Authors:  Frank Maldarelli; Sarah Palmer; Martin S King; Ann Wiegand; Michael A Polis; JoAnn Mican; Joseph A Kovacs; Richard T Davey; Diane Rock-Kress; Robin Dewar; Shuying Liu; Julia A Metcalf; Catherine Rehm; Scott C Brun; George J Hanna; Dale J Kempf; John M Coffin; John W Mellors
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.